1. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008; 26 (Suppl. 51): 35–61.
2. Gabriel SE. Why do people with rheumatoid arthritis still die prematurely? Ann Rheum Dis 2008; 67 (suppl. III): 30–4.
3. Avina-Zubieta JA, Choi HK, Sadatsafavi M et al. Risk of Cardiovascular Mortality in Patients With Rheumatoid Arthritis: A Meta-Analysis of Observational Studies Arthritis & Rheumatism. Arthr Care Res 2008; 59 (12): 1690–7.
4. Esdaile JM, Abrahamowicz M, Grodzicky T et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthr Rheum 2001; 44: 2331–7.
5. Bessant R, Hingorani A, Patel L et al. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford) 2004; 43: 924–9.
6. Fischer LM, Schlienger RG, Matter C et al. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 2004; 93: 198–200.
7. Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408–15.
8. Jonsson H, Nived O, Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 1989; 68: 141–50.
9. Bjornadal L, Yin L, Granath F et al. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964–95. J Rheumatol 2004; 31: 713–9.
10. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthr Rheum 1999; 42: 338–46.
11. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93: 513–9.
12. Meune C, Touze E, Trinqurte L et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analisis of cohort studies. Rheumatology 2009, doi: 10.1093/rheumatology/kep252.
13. Westerweel PE, Remco KMAC Luyten, Koomans HA et al. Premature Atherosclerotic Cardiovascular Disease in Systemic Lupus Erythematosus. Arthr Rheum 2007; 56 (5): 51384–96.
14. van Halm, Peters VP, Voskuyl MJ et al. Rheumatoid arthritis versus type 2 diabetes as a risk factor for cardiovascular disease: a cross-sectional study. Ann Rheum Dis 2009; 68: 1395–400.
15. Goodson N. Coronary artery disease and rheumatoid arthritis. Curr Opin Rheumatol 2002; 14: 115–20.
16. Maradit Kremers H, Crowson CS, Therneau TM et al. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients. A population-based cohort study. Arhr Rheum 2008; 58; 8: 2268–74.
17. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005; 35: 8–17.
18. Gerli R, Bartoloni Bocci E, Sherer Y et al. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 724–5.
19. Maradit-Kremers H, Crowson CS, Nicola PJ et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthr Rheum 2005; 52: 402–11.
20. Maradit-Kremers H, Nicola PJ, Crowson CS et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthr Rheum 2005; 52: 722–32.
21. Aubry MC, Maradit-Kremers H, Reinalda MS et al. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol 2007; 34: 937–42.
22. Abu-Shakra M, Urowitz MB, Gladman DD et al. Mortality studies in systemic lupus erythematosus: results from a single center. I. Causes of death. J Rheumatology 1995; 22: 1259–64.
23. Попкова Т.В. Атеросклеротическое поражение сосудов при системной красной волчанке и ревматоидном артрите. Автореф. дис. … д-ра мед. наук. М., 2009.
24. Panoulas VF, Douglas KM, Milionis HJ et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 1477–82.
25. Solomon DH, Curhan GC, Rimm EB et al. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthr Rheum 2004; 50: 3444–9.
26. Goodson NJ, Silman AJ, Pattison DJ et al. Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis. Rheumatology (Oxford) 2004; 43: 731–6.
27. Насонов Е.Л. Проблема атеротромбоза в ревматологии. Вестн. РАМН. 2003; 7: 6–10.
28. Avalos I, Rho YH, Chung CP et al. Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Rheumatol 2008; 26 (Suppl. 51): 5–13.
29. Попкова Т.В., Алекберова З.С., Александрова Е.Н. и др. Факторы риска кардиоваскулярных нарушений и атеросклероза при системной красной волчанке. Науч.-практич. ревматол. 2004; 4: 10–4.
30. Насонов Е.Л., Попкова Т.В. Кардиоваскулярные проблемы ревматологии. Науч.-практич. ревматол. 2004; 4: 4–9
31. Del Rincon I, Williams K, Stern MP et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthr Rheum 2001; 44: 2737–45.
32. Dessein PH, Joffe BI, Veller MG et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005; 32: 435–42.
33. Sattar N, McCarey DW, Capell H et al. Eхрlaining how «high-grade» systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957–63.
34. Попкова Т.В., Новикова Д.С., Новиков А.А. и др. Роль нарушений в системе транспорта холестерина крови в развитии ареросклероза при ревматоидном артрите. Науч.-практич. ревматол. 2007; 5: 4–10.
35. Nielen MJ, van Halm VP, Nurmohamed MT et al. Rheumatoid arthritis is preceded by a preclinical phase, characterized by increased C-reactive protein levels and a more atherogenic lipid profile. Arthr Rheum 2003; 48: 344.
36. van Halm VP, Nielen MJ, Nurmohamed MT et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2006; 000: 1–5.
37. Khovidhunkit W, Kim MS, Memon RA. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004; 45: 1169–96.
38. Peterson MJ, Symmons DP, McCarrey DW et al. Cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis – EULAR TASK FORCE «Cardiovascular risk management in RA». Ann Rheum Dis 2008; 67 (suppl. II): 310.
39. Choi E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009; 68: 460–9.
40. Насонов Е.Л. Антифосфолипидный синдром. М.: Литтерра, 2004.
41. Maradit-Kremers HM, Nicola PJ, Crowson CS et al. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthr Rheum 2004; 50: 3450–7.
42. Stavropoulos-Kalinoglou, Metsios GS, Koutedakis Y et al. Redefining overweight and obesity in rheumatoid arthritis patients. Ann Rheum Dis 2007; 66: 1316–21.
43. Попкова Т.В., Новикова Д.С., Герасимова Е.В. и др. Метаболический синдром у больных системной красной волчанкой. Науч.-практич. ревматол. 2008; 4: 14–20.
44. Dessein PH, Tobias M, Veller MG. Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 2006; 33: 2425–32.
45. Ревматология: национальное руководство. Под ред. Е.Л.Насонова, В.А.Насоновой. М.: ГЭОТАР-Медиа, 2008.
46. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 115–26.
47. Falaschi F, Ravelli A, Martignon A et al. Nephrotic-range proteinutia, the major risk factor for early athrosclerosis in juvenile-onset systemic lupus erythematosus. Arthr Rheum 2001; 43: 1405–9.
48. Font J, Ramos-Casals, Cervera R et al. Cardiovascular risk factors and long-term outcome of lupus nephritis. Q J Med 2001; 94: 19–26.
49. Roman MJ, Shanker B-A, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399–406.
50. Doria A, Shoenfeld Y, Wu R et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 1071–7.
51. Dessein PH, Joffe BI. When is a patient with rheumatoid arthritis at risk for cardiovascular disease? J Rheumatol 2006; 33: 201–3.
52. Naranjo A, Sokka T, Descalzo MA et al. QUEST-RA Group. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthr Res Ther 2008; 10: 30.
53. Попкова Т.В., Новикова Д.С., Писарев В.В. и др. Факторы риска кардиоваскулярных заболеваний при ревматоидном артрите. Науч.-практич. ревматол. 2009; 3: 4–11.
54. Peters MJ, Symmons PM, McCarey D et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2009; doi: 10.1136/ard.2009.113696.
55. Ревматология: Клинические рекомендации. Под ред. акад. РАМН Е.Л.Насонова. М.: ГЭОТАР-Медиа, 2010.